Lipomedix Pharmaceuticals Ltd.

Lipomedix is an Israeli private, clinical stage company developing innovative agents for cancer therapy and focused on liposome-based drug delivery.

Lipomedix has developed PROMITIL®, a pegylated liposome delivery system platform based on the encapsulation of a new chemical entity known as MLP, a proprietary prodrug form of the potent anticancer and radiosensitizing agent mitomycin C. The extraordinary pharmacological properties of Promitil® can turn it into a state-of-the-art anti-cancer nano-drug, especially in cancers derived from the gastrointestinal tract, and into an ideal radio-sensitizer in chemoradiotherapy with potentially curative effect in multiples types of cancer.

Promitil has completed phase 1A and 1B. FDA has recently approved the initiation of a randomized Phase 2B US-based international study of Promitil in advanced colorectal cancer.

In addition, Lipomedix is conducting a phase 1B study in 2 medical centers in Israel to examine the safety and efficacy of Promitil-based chemo-radiotherapy.

Lipomedix is positioning Promitil® as a powerful, safe, and attractive tool for use as single agent or in combination with chemotherapy, immunotherapy, and, as mentioned above, radiotherapy. Further clinical studies of Promitil®-based combination therapy in several indications with potential orphan drug designation status are currently under planning.